Massachusetts is currently home to 3147 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
fMRI and IVCM Cornea Microscopy of CXL in Keratoconus
NCT04439552
Recruiting
Evaluation of neuroplasticity of pain pathways and corneal afferent nerve regeneration following corneal crosslinking (CXL) in keratoconus patients using fMRI and corneal In Vivo Confocal Microscopy (IVCM).
Gender:
ALL
Ages:
Between 8 years and 35 years
Trial Updated:
02/07/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Pain, Postoperative, Pain, Chronic, Pain, Acute, Surgical Injury, Surgical Wound, Cornea Injury, Cornea, Keratoconus
Register for Updates
Strength After Breast Cancer
NCT06052488
Recruiting
The goal of this study is to explore whether a group exercise program called Strength After Breast Cancer can be delivered in an outpatient physical therapy clinic to improve physical function among women after treatment for breast cancer. The main questions this study aims to answer are: * Can the Strength After Breast Cancer program and the associated outcome battery be successfully delivered in an outpatient physical therapy clinic at Massachusetts General Hospital and do participants find... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: MGH Institute of Health Professions, Boston, Massachusetts
Conditions: Breast Cancer
Register for Updates
Interstage Monitoring Using an Implantable Loop Recorder: A Pilot Study
NCT05744934
Recruiting
The primary objective of this investigation is to evaluate the feasibility and safety of implantable loop recorder implantation (using the LUX-DX™) in newborns undergoing stage 1 palliation. The secondary objective of the investigation is to evaluate the feasibility of continuous measurement of heart rate and arrhythmia using an implantable loop recorder (LUX-Dx™) during the interstage period. An implantable loop recorder will be placed at the time of chest closure following stage 1 palliation... Read More
Gender:
ALL
Ages:
30 days and below
Trial Updated:
02/06/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Univentricular Heart
Register for Updates
BostonGene-Integrated Genomic Registry (BIGR)
NCT04991922
Recruiting
The purpose of this project is to develop a comprehensive database of genomic, transcriptomic, molecular, and clinical characteristics of oncology patients to discover, define, and develop genomic and transcriptomic markers to improve future clinical outcomes across cancer types
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: BostonGene, Waltham, Massachusetts
Conditions: Malignancy
Register for Updates
Anamorelin Study for Advanced Pancreatic Cancer
NCT04844970
Recruiting
Multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of anamorelin HCl. Approximately 100 subjects with advanced PDAC and cachexia will be randomized 1:1 to anamorelin HCl 100 mg or placebo, taken orally once daily (QD) for a total of 25 weeks. Subjects will be instructed to take the study drug at least 1 hour before their first meal of the day
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: Lahey Hospital & Medical Center, Burlington, Massachusetts
Conditions: Metastatic Pancreatic Cancer
Register for Updates
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
NCT04215809
Recruiting
Assess the safety and tolerability, identify dose-limiting toxicities (DLT) and determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) of APG-2575.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
02/06/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: CLL/SLL
Register for Updates
Orphan Europe Carbaglu® Surveillance Protocol
NCT03409003
Recruiting
The purpose of this study is to conduct post-marketing surveillance of carglumic acid (Carbaglu) to obtain long-term clinical safety information. Carglumic acid was approved by the United States Food and Drug Administration (FDA) for treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Much of the FDA-required data is already collected through the Longitudinal Study of Urea Cycle Disorders (RDCRN Protocol #5101). This study will collect additional data on advers... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/06/2024
Locations: Children's Hospital Boston (UCDC New England Center), Boston, Massachusetts
Conditions: N-acetylglutamate Synthase (NAGS) Deficiency
Register for Updates
M-Vizion™ Macroscopic Radiographic Study
NCT05721859
Recruiting
Study of the patient's subsidence after revision hip arthroplasty by assessing gross stem subsidence in the femoral canal.
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
02/05/2024
Locations: New England Baptist Hospital, Boston, Massachusetts
Conditions: Revision Hip Arthroplasty
Register for Updates
Efficacy and Safety Study of OMTX705, Monotherapy and Pembrolizumab-combined, in Subjects With Advanced Solid Tumors.
NCT05547321
Recruiting
Open-label, two parallel arm, multicenter, Phase 1 dose-escalation study to evaluate the safety and tolerability of OMTX705, both as monotherapy or in combination with pembrolizumab in the treatment of patients with advanced or metastatic cancer in whom there is no available standard therapeutic option.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/02/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Advanced Solid Tumor
Register for Updates
Feasibility of the Comfort Measures Only Time Out (CMOT)
NCT05861323
Recruiting
Nearly 25% of Americans die in intensive care units (ICUs). Most deaths in ICUs are expected and involve the removal of ventilator support, or palliative withdrawal of mechanical ventilation (WMV). Prior work by the Principal Investigator (PI) found that patient suffering can be common; with 30-59% of patients going through this process experiencing distress. Thus, experts and national organizations have called for evidence to inform guidelines for WMV. This research study will 1) develop and re... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/01/2024
Locations: Beth Israel Deaconess Medical center, Boston, Massachusetts
Conditions: End of Life, Respiratory Failure, Ventilatory Failure, Coma, Aging
Register for Updates
Studying Pathways of Resistance in KRAS-driven Cancers
NCT05272423
Recruiting
Up to 250 patients from anywhere in the United States can remotely consent and participate to have plasma drawn locally and submitted to Foundation Medicine, Inc. (FMI), for the FoundationOne® Liquid Biopsy Assay. Patients who have had resistance mechanisms determined through other assays can also consent to share these data. The Investigator(s) will compare mechanisms of acquired resistance across drugs (e.g. sotorasib vs adagrasib) and between tumor types (e.g. NSCLC vs CRC) to determine if di... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/01/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: KRAS P.G12C
Register for Updates
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
NCT04137900
Recruiting
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of TAB004 monotherapy and in combination with toripalimab and to describe the PK profile of toripalimab when administered with TAB004, 2) evaluate antitumor activity of TAB004... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/01/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Advanced Unresectable Solid Tumor, Metastatic Solid Tumor
Register for Updates